Today in Focus: APLD, IMMX, GFS

Trading Services I Use in my Trading:

StockAnalysis.com - I’ve been using Stock Analysis as an affordable but reliable method of looking at New and Upcoming IPOs, Earnings Calendars and most notably KPIs (Key Performance Indicators). Stock Analysis allows you to view the KPIs for many companies with up to date metrics and segments that you can cross reference against Earnings Results. This is incredibly important when understanding what metrics move a stock. At $65 per year it’s a no brainer. They’ve given me a discount code if you use IRISHBORNINVESTOR they will give you another 10% Off.

Market Condition: Chop Mode Likely

Commentary: A day like yesterday is difficult for my style of trading as there are no catalysts but stocks are running. These are days that FOMO needs to be controlled. I’ve become better at it but I can still feel it. I had a stop out in MXL and CIFR but IREN worked well for me yesterday from my delayed reaction list. It always reinforces to me that my setup is catalysts and buying continuations or breakouts is not something I’m particularly good at!

Market had a slingshot move yesterday. Nice gap down today which we want to see buying kick in. We likely range out here in the market for a period. I’m focusing on catalysts with good charts and managing my existing positions. Lot’s of names acting well despite the pullback.

Caution and don’t rush new exposure here. IPO market will be really pumping this year. Patience will pay and be brave with existing positions follow strict trim rules and try to leave winners run.

In Play

GFS:  Announced Quantum Business Unit & Government Investment

Key Metrics GFS: Industry Group: Semiconductors, Market Cap: 44.71B, Float: 132.68M, Short Interest: 7.48%, Days to Cover: 2.42, Sales Y/Y TTM: 0.80%, EPS Y/Y TTM: 511.39%, Earnings: May 05 BMO, Exchange: NASDAQ

Catalyst: Announced the launch of "Quantum Technology Solutions," a dedicated quantum computing business unit. he announcement is anchored by a Letter of Intent from the U.S. Department of Commerce to award GF $375M under the CHIPS R&D program, plus a separate agreement granting Commerce a ~1% equity stake in GF.

Several Quantum names moving on this. It’s an LOI so might not have follow through but the GFS deal is one of the least dilutive and the stock has momentum from other business vs. many of the Quantum names which are just BS. Chart is good. I’m looking for a push through $80 otherwise I’m not overly interested.

APLD: 15 Year Lease Agreement, $7.5b Base

Key Metrics APLD: Industry Group: Information Technology Services, Market Cap: 12.43B, Float: 258.69M, Short Interest: 30.95%, Days to Cover: 3.80, Sales Y/Y TTM: 60.70%, EPS Y/Y TTM: 46.26%, Earnings: Apr 08 AMC, Exchange: NASDAQ

Catalyst: Applied Digital announced a signed 15-year take-or-pay lease for its fourth AI campus, Polaris Forge 3 (300 MW critical IT load / ~430 MW utility power, 600+ acres, northern state location undisclosed). The counterparty is the same unnamed U.S. investment-grade hyperscaler from the April 23 Delta Forge 1 deal. Contract value: ~$7.5B base, ~$18.2B with renewal options. This pushes APLD's total contracted revenue to $31B base / $73B with options across 1,200 MW of critical IT load at four campuses. Operations anticipated to commence August 2027.

Top tier chart on weekly and daily and monthly. Signed deal not LOI or MOU. High Short interest.

IMMX:  Interim update from NEXICART-2

Key Metrics IMMX: Industry Group: Biotechnology, Market Cap: 534.32M, Float: 41.32M, Short Interest: 7.31%, Days to Cover: 3.98, Sales Y/Y TTM: -, EPS Y/Y TTM: -27.17%, Earnings: Feb 25, Exchange: NASDAQ

Catalyst: Immix Biopharma released a brief interim update from NEXICART-2 (NCT06097832), a 45-patient single-arm Phase 2 trial of NXC-201 — a sterically-optimized BCMA-targeted CAR-T — in relapsed/refractory AL amyloidosis. All four MRD-negative patients previously presented at ASH 2025 have now converted to confirmed complete response (CR), bringing the cumulative CR rate to 95% (19/20 patients) in the first 20 enrolled. All CRs were achieved within one year of dosing, with zero relapses reported to date.

This is a follow on data readout. Clinically quite strong despite just being an interim update. Caveat: They announced a $150m offering at the same time which has depressed the price but I think the market can eat it. Nice chart with good potential.

Current Positions: MRAM, BW, SBUX, AAPL, NVDA, GOOG, BAND, AKAM, TWLO, DELL, TH, INOD, IREN, CMPS, FIG

Delayed Reaction Watchlist (TradingView Link)

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}